- Total prescriptions (TRx) for Gilead's (GILD +1.3%) hepatitis C pill Sovaldi rose almost 70% to 1,764 in the week ended January 10, although it's worth pointing out that previous weeks included the holidays.
- "Still, the Solvadi scripts to date are impressive and point to early, strong demand for the new Hep C pill," says Adam Feuerstein.
- ISI analyst Mark Schoenebaum says: "If TRx were to only remain flat through year end and we assume 20% discounting on price and a similar capture rate to [Vertex Pharma's (VRTX)] Incivek for sales...we estimate that FY 2014 sales could be ~$2.4 B."
Gilead's hepatitis C drug Sovaldi gets off to strong start
Jan 21 2014, 09:15 ET